{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:04:10Z","timestamp":1793138650058,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"DKFZ-Bayer Alliance","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,10,8]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The metabolism of tryptophan to kynurenines (KYN) by indoleamine-2,3-dioxygenase or tryptophan-2,3-dioxygenase is a key pathway of constitutive and adaptive tumor immune resistance. The immunosuppressive effects of KYN in the tumor microenvironment are predominantly mediated by the aryl hydrocarbon receptor (AhR), a cytosolic transcription factor that broadly suppresses immune cell function. Inhibition of AhR thus offers an antitumor therapy opportunity via restoration of immune system functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression of AhR was evaluated in tissue microarrays of head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). A structure class of inhibitors that block AhR activation by exogenous and endogenous ligands was identified, and further optimized, using a cellular screening cascade. The antagonistic properties of the selected AhR inhibitor candidate BAY 2416964 were determined using transactivation assays. Nuclear translocation, target engagement and the effect of BAY 2416964 on agonist-induced AhR activation were assessed in human and mouse cancer cells. The immunostimulatory properties on gene and cytokine expression were examined in human immune cell subsets. The in vivo efficacy of BAY 2416964 was tested in the syngeneic ovalbumin-expressing B16F10 melanoma model in mice. Coculture of human H1299 NSCLC cells, primary peripheral blood mononuclear cells and fibroblasts mimicking the human stromal-tumor microenvironment was used to assess the effects of AhR inhibition on human immune cells. Furthermore, tumor spheroids cocultured with tumor antigen-specific MART-1 T cells were used to study the antigen-specific cytotoxic T cell responses. The data were analyzed statistically using linear models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AhR expression was observed in tumor cells and tumor-infiltrating immune cells in HNSCC, NSCLC and CRC. BAY 2416964 potently and selectively inhibited AhR activation induced by either exogenous or endogenous AhR ligands. In vitro, BAY 2416964 restored immune cell function in human and mouse cells, and furthermore enhanced antigen-specific cytotoxic T cell responses and killing of tumor spheroids. In vivo, oral application with BAY 2416964 was well tolerated, induced a proinflammatory tumor microenvironment, and demonstrated antitumor efficacy in a syngeneic cancer model in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings identify AhR inhibition as a novel therapeutic approach to overcome immune resistance in various types of cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-007495","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:10:33Z","timestamp":1699963833000},"page":"e007495","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":95,"title":["Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04069026","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christina","family":"Kober","sequence":"first","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"},{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Roewe","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-3921","authenticated-orcid":false,"given":"Norbert","family":"Schmees","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Roese","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Roehn","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-396X","authenticated-orcid":false,"given":"Benjamin","family":"Bader","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Stoeckigt","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Prinz","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ty\u00e1s","family":"Gorj\u00e1n\u00e1cz","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge Gottfried","family":"Roider","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Olesch","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"},{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Leder","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Irlbacher","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Lesche","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lefranc","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Oezcan-Wahlbrink","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"},{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita Sati","family":"Batra","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmeen","family":"Elmadany","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Carretero","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"},{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Sahm","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Oezen","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Cichon","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baumann","sequence":"additional","affiliation":[{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sadik","sequence":"additional","affiliation":[{"name":"Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane A","family":"Opitz","sequence":"additional","affiliation":[{"name":"Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmar","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo V","family":"Hartung","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertolt","family":"Kreft","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rienk","family":"Offringa","sequence":"additional","affiliation":[{"name":"DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany"},{"name":"Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany"},{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Gutcher","sequence":"additional","affiliation":[{"name":"Bayer AG, Pharmaceutical Division, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2025100304242758000_11.11.e007495.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0664-6"},{"key":"2025100304242758000_11.11.e007495.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0016-5"},{"key":"2025100304242758000_11.11.e007495.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113873109"},{"key":"2025100304242758000_11.11.e007495.4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000492849","article-title":"The Clinicopathological and Prognostic significance of Ido1 expression in human solid tumors: evidence from a systematic review and meta-analysis","volume":"49","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2025100304242758000_11.11.e007495.5","doi-asserted-by":"publisher","DOI":"10.1038\/nm934"},{"key":"2025100304242758000_11.11.e007495.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2285"},{"key":"2025100304242758000_11.11.e007495.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature10491"},{"key":"2025100304242758000_11.11.e007495.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196"},{"key":"2025100304242758000_11.11.e007495.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2925"},{"key":"2025100304242758000_11.11.e007495.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.3748"},{"key":"2025100304242758000_11.11.e007495.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0702-0"},{"key":"2025100304242758000_11.11.e007495.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.038"},{"key":"2025100304242758000_11.11.e007495.13","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq024"},{"key":"2025100304242758000_11.11.e007495.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903670"},{"key":"2025100304242758000_11.11.e007495.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3846"},{"key":"2025100304242758000_11.11.e007495.16","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12092"},{"key":"2025100304242758000_11.11.e007495.17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.it.2018.10.010","article-title":"The aryl hydrocarbon receptor: connecting immunity to the Microenvironment","volume":"39","author":"Shinde","year":"2018","journal-title":"Trends Immunol"},{"key":"2025100304242758000_11.11.e007495.18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the immune response by the aryl hydrocarbon receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"2025100304242758000_11.11.e007495.19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cei.12352","article-title":"Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived Dendritic cells","volume":"177","author":"Wang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025100304242758000_11.11.e007495.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01243","article-title":"Tryptophan catabolism as immune mechanism of primary resistance to anti-PD-1","volume":"11","author":"Botticelli","year":"2020","journal-title":"Front Immunol"},{"key":"2025100304242758000_11.11.e007495.21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2025100304242758000_11.11.e007495.22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript Quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2025100304242758000_11.11.e007495.23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3581"},{"key":"2025100304242758000_11.11.e007495.24","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor Microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2025100304242758000_11.11.e007495.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019823","article-title":"The Indoleamine-2,3-Dioxygenase (IDO) inhibitor 1-methyl-D-Tryptophan Upregulates Ido1 in human cancer cells","volume":"6","author":"Opitz","year":"2011","journal-title":"PLoS One"},{"key":"2025100304242758000_11.11.e007495.26","doi-asserted-by":"crossref","unstructured":"Li H , Bullock K , Gurjao C , et al . Metabolomic adaptations and correlates of survival to immune Checkpoint blockade. Nat Commun 2019;10. doi:10.1038\/s41467-019-12361-9","DOI":"10.1038\/s41467-019-12361-9"},{"key":"2025100304242758000_11.11.e007495.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"2025100304242758000_11.11.e007495.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122046","article-title":"Accumulation of an endogenous Tryptophan-derived metabolite in colorectal and breast cancers","volume":"10","author":"Puccetti","year":"2015","journal-title":"PLoS One"},{"key":"2025100304242758000_11.11.e007495.29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nbt.4180","article-title":"Reversal of Indoleamine 2,3-Dioxygenase-mediated cancer immune suppression by systemic Kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2025100304242758000_11.11.e007495.30","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0984"},{"key":"2025100304242758000_11.11.e007495.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.5.2895"},{"key":"2025100304242758000_11.11.e007495.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014465107"},{"key":"2025100304242758000_11.11.e007495.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.07.156"},{"key":"2025100304242758000_11.11.e007495.34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081438"},{"key":"2025100304242758000_11.11.e007495.35","doi-asserted-by":"publisher","DOI":"10.1038\/nature06881"},{"key":"2025100304242758000_11.11.e007495.36","doi-asserted-by":"publisher","DOI":"10.1080\/15476910802019037"},{"key":"2025100304242758000_11.11.e007495.37","doi-asserted-by":"publisher","DOI":"10.1006\/taap.2002.9537"},{"key":"2025100304242758000_11.11.e007495.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322292111"},{"key":"2025100304242758000_11.11.e007495.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1302856110"},{"key":"2025100304242758000_11.11.e007495.40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the clinical development of Epacadostat and other Indoleamine 2,3-Dioxygenase 1 inhibitors (Ido1) for human cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front Oncol"},{"key":"2025100304242758000_11.11.e007495.41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602"},{"key":"2025100304242758000_11.11.e007495.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.013"},{"key":"2025100304242758000_11.11.e007495.43","doi-asserted-by":"crossref","first-page":"18691","DOI":"10.1002\/cam4.6484","article-title":"The Tryptophan-Kynurenine pathway in Immunomodulation and cancer metastasis","volume":"12","author":"Basson","year":"2023","journal-title":"Cancer Med"},{"key":"2025100304242758000_11.11.e007495.44","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1240858","article-title":"The stress kinase Gcn2 does not mediate suppression of antitumor T cell responses by Tryptophan catabolism in experimental Melanomas","volume":"5","author":"Sonner","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100304242758000_11.11.e007495.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1191536"},{"key":"2025100304242758000_11.11.e007495.46","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.073643"},{"key":"2025100304242758000_11.11.e007495.47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8402","article-title":"Metabolic adaptation of ovarian tumors in patients treated with an Ido1 inhibitor constrains antitumor immune responses","volume":"14","author":"Odunsi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100304242758000_11.11.e007495.48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/ijms22010387","article-title":"How the AHR became important in cancer: the role of chronically active AHR in cancer aggression","volume":"22","author":"Wang","year":"2020","journal-title":"IJMS"},{"key":"2025100304242758000_11.11.e007495.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00430-8"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:24:35Z","timestamp":1759490675000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,14]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/jitc-2023-007495"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007495","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}